Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DATSCAN

« Back to Dashboard
Datscan is a drug marketed by Ge Hlthcare Inc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has twenty patent family members in eleven countries.

The generic ingredient in DATSCAN is ioflupane i-123. One supplier is listed for this compound. Additional details are available on the ioflupane i-123 profile page.

Summary for Tradename: DATSCAN

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Clinical Trials for: DATSCAN

A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms
Status: Completed Condition: Parkinsonian Syndromes

DaTSCAN Imaging in Aging and Neurodegenerative Disease
Status: Enrolling by invitation Condition: Dementia; Parkinsonism; Mild Cognitive Impairment; REM Sleep Behavior Disorder

Validation of DaTscan for Detection of Parkinson Disease Related Disorders
Status: Enrolling by invitation Condition: Parkinson Disease; Movement Disorders

Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies
Status: Completed Condition: Dementia With Lewy Bodies

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
Status: Active, not recruiting Condition: Essential Tremor; Parkinson's Disease

Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls
Status: Completed Condition: Amyotrophic Lateral Sclerosis

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics
Status: Not yet recruiting Condition: Parkinson Disease

Co-LEsions in Alzheimer Disease and Related Disorders
Status: Not yet recruiting Condition: Alzheimer's Disease; Cerebrovascular Disease; Lewy Body Disease

DatScan With Prototype Collimator
Status: Not yet recruiting Condition: Parkinson Disease

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
Status: Completed Condition: Lewy Body Dementia; Non-DLB Dementia; Alzheimer’s; Vascular Dementia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Hlthcare Inc
DATSCAN
ioflupane i-123
SOLUTION;INTRAVENOUS022454-001Jan 14, 2011RXYes5,310,912<disabled>Y<disabled>
Ge Hlthcare Inc
DATSCAN
ioflupane i-123
SOLUTION;INTRAVENOUS022454-001Jan 14, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DATSCAN

Country Document Number Publication Date
World Intellectual Property Organization (WIPO)9501184Jan 12, 1995
Spain2189792Jul 16, 2003
Germany10399020May 04, 2005
Japan3731005Jan 05, 2006
Germany10399020Sep 18, 2003
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc